Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. COVID-19 and the brain: impact on nuclear medicine in neurology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. High Sympathetic Activity in Raynaud's Disease

    Publikation: Bidrag til tidsskriftKonferenceartikelForskningpeer review

  4. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of blood glucose and body weight on image quality in brain [F-18]FDG PET imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Vis graf over relationer

AIM: To assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer's disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia.

METHODS: A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method.

RESULTS: The level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs-including those where study evidence was poor or lacking-based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed.

CONCLUSION: Although there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Nuclear Medicine and Molecular Imaging
Vol/bind45
Udgave nummer9
Sider (fra-til)1509-1525
Antal sider17
ISSN1619-7070
DOI
StatusUdgivet - jul. 2018

ID: 56524690